| 前收盘价格 | 0.500 |
| 收盘价格 | 0.482 |
| 成交量 | 8,716 |
| 平均成交量 (3个月) | 169,324 |
| 市值 | 112,457,920 |
| 股市价格/股市净资产 (P/B) | 208.12 |
| 52周波幅 | |
| 利润日期 | 25 Feb 2025 - 3 Mar 2025 |
| 营业利益率 (TTM) | -369.31% |
| 稀释每股收益 (EPS TTM) | -0.100 |
| 季度收入增长率 (YOY) | -39.40% |
| 总债务/股东权益 (D/E MRQ) | 455.33% |
| 流动比率 (MRQ) | 0.340 |
| 营业现金流 (OCF TTM) | -13.01 M |
| 杠杆自由现金流 (LFCF TTM) | -7.74 M |
| 资产报酬率 (ROA TTM) | -238.11% |
| 股东权益报酬率 (ROE TTM) | -1,277.62% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | RECCE LTD FPO [RCE] | - | - |
AIStockmoo 评分
0.8
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.75 |
|
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 33.58% |
| 机构持股比例 | 6.53% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合